{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:03:48Z","timestamp":1792213428920,"version":"4.4.0"},"reference-count":9,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,3,1]],"date-time":"2024-03-01T00:00:00Z","timestamp":1709251200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1016\/j.euf.2024.05.012","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:19:25Z","timestamp":1718237965000},"page":"222-223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer"],"prefix":"10.1016","volume":"10","author":[{"given":"Samuel","family":"McInerney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2024.05.012_b0005","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1177\/1758834009337776","article-title":"Review: novel agents for advanced bladder cancer","volume":"1","author":"Sonpavde","year":"2009","journal-title":"Ther Adv Med Oncol"},{"key":"10.1016\/j.euf.2024.05.012_b0010","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.539527","article-title":"Novel combination therapies for the treatment of bladder cancer","volume":"10","author":"Peng","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.euf.2024.05.012_b0015","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","article-title":"Erdafitinib or chemotherapy in advanced or metastatic urothelial carcinoma","volume":"389","author":"Loriot","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euf.2024.05.012_b0020","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.euf.2024.05.012_b0025","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1188\/21.CJON.E1-E9","article-title":"Enfortumab vedotin: nursing perspectives on the management of adverse events in patients with locally advanced or metastatic urothelial carcinoma","volume":"25","author":"Pace","year":"2021","journal-title":"Clin J Oncol Nurs"},{"key":"10.1016\/j.euf.2024.05.012_b0030","doi-asserted-by":"crossref","first-page":"e223","DOI":"10.1093\/oncolo\/oyac001","article-title":"Management of dermatologic events associated with the Nectin-4-directed antibody-drug conjugate enfortumab vedotin","volume":"27","author":"Lacouture","year":"2022","journal-title":"Oncologist"},{"issue":"16 Suppl","key":"10.1016\/j.euf.2024.05.012_b0035","article-title":"Incidence and risk of peripheral sensory neuropathy with enfortumab vedotin in patients with advanced urothelial cancer: a systematic review and meta-analysis","volume":"41","author":"Shah","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2024.05.012_b0040","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/psp4.12727","article-title":"Erdafitinib\u2019s effect on serum phosphate justifies its pharmacodynamically guided dosing in patients with cancer","volume":"11","author":"Dosne","year":"2022","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.euf.2024.05.012_b0045","unstructured":"Janssen. BALVERSA (erdafitinib). https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/BALVERSA-pi.pdf."}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000750?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456924000750?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,13]],"date-time":"2025-04-13T12:01:43Z","timestamp":1744545703000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456924000750"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3]]},"references-count":9,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["S2405456924000750"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.012","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2024,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toxicities of Novel Agents for the Treatment of Advanced Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2024.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}